International Journal For Multidisciplinary Research

E-ISSN: 2582-2160   •   Impact Factor: 9.24

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 7, Issue 2 (March-April 2025) Submit your research before last 3 days of April to publish your research paper in the issue of March-April.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 7 Issue 2
March-April 2025

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

Comparing the Efficacy and Safety of Different DOACs (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) for Stroke Prevention in Atrial Fibrillation

Author(s) Dr. Dinesh Kumar Balamurugan, Collins Gilbert, Mohammed Amann, Harsh Bansal
Country India
Abstract Atrial fibrillation (AF) is a major risk factor for ischemic stroke, necessitating effective anticoagulation therapy. Direct oral anticoagulants (DOACs), including dabigatran, rivaroxaban, apixaban, and edoxaban, have revolutionized stroke prevention by offering comparable or superior efficacy to warfarin with improved safety profiles and fewer monitoring requirements. However, differences in efficacy, bleeding risks, and patient-specific considerations make choosing the optimal DOAC complex.This systematic review evaluates and compares the efficacy and safety of the four major DOACs for stroke prevention in AF patients. A comprehensive literature search was conducted across multiple databases to identify relevant randomized controlled trials (RCTs) and observational studies. Key outcomes assessed include stroke prevention, major bleeding events, intracranial hemorrhage, and gastrointestinal bleeding. Additionally, subgroup analyses based on renal function, age, and prior bleeding risk were explored to determine the most suitable DOAC for different patient populations.
Findings indicate that while all DOACs significantly reduce stroke incidence compared to warfarin, they exhibit varying safety profiles. Apixaban demonstrates the lowest major bleeding risk, making it particularly beneficial for elderly patients or those at high bleeding risk. Dabigatran, while highly effective in stroke prevention, is associated with increased gastrointestinal bleeding. Rivaroxaban and edoxaban offer non-inferior stroke prevention but require careful dose adjustments in patients with renal impairment.
Given the increasing global burden of AF, optimizing anticoagulation therapy is critical in reducing stroke-related morbidity and mortality. This review highlights the importance of individualized DOAC selection based on patient-specific factors, ensuring optimal balance between efficacy and safety. Further research into long-term adherence, real-world effectiveness, and direct head-to-head comparisons of DOACs will help refine clinical guidelines and improve patient outcomes.
Keywords Direct Oral Anticoagulants, Dabigatran, Rivaroxaban, Apixaban, Edoxaban, Stroke Prevention, Atrial Fibrillation
Field Biology
Published In Volume 7, Issue 2, March-April 2025
Published On 2025-03-27
DOI https://doi.org/10.36948/ijfmr.2025.v07i02.39695
Short DOI https://doi.org/g8935r
View / Download PDF File

Share this



E-ISSN 2582-2160
CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 7 Isu 2Cover Page Vol 7 Isu 1Cover Page Vol 6 Isu 6

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJFMR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-9687-828-838 editor@ijfmr.com